We identified 34 protein-altering mutations that arose during exposure to BCR inhibition, including the known DLBCL driver genes—ARID1A and CARD11 (Figs 2A and 2B and Data Supplement). The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.